Neumora Therapeutics Inc (NMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.31-2.96%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NMRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
NMRA — CEO transition
Dated 2026-08-14
CEO — Joshua Pinto: The CEO role was filled by an internal promotion of the current President, indicating a planned succession rather than an unexpected departure.
Why it matters: Starting the Phase 1 study is critical for NMRA-215's advancement. It shows the drug is moving closer to market.
Supportive ifThe company initiates the Phase 1 study for NMRA-215 by the end of 2026.
Worry ifThe Phase 1 study for NMRA-215 does not start by the end of 2026.
Why it matters: How long the cash lasts affects the company's ability to fund operations and projects. It's critical for survival.
Worry ifA new announcement says cash reserves can keep operations going until Q3 2027.
Less concerning ifA warning that cash reserves will run out before Q3 2027.
Why it matters: Submitting the IND is a key step for NMRA-215's clinical development. It shows progress in treating obesity and heart diseases.
Supportive ifThe company submits the IND for NMRA-215 by the end of Q4 2026.
Worry ifThe IND submission is delayed beyond Q4 2026.
Why it matters: Workforce cuts can affect productivity and project timelines. This could slow down drug development.
Worry ifA report shows operations are stable even with fewer workers.
Less concerning ifDelays or slowdowns in projects after workforce cuts.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$247 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $745 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,453 loss on $10,000 · 74.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Data from NMRA-511 will inform the next steps in treating Alzheimer’s disease agitation. Positive data could validate the program's potential.
Supportive ifThe company reports positive data from the MAD expansion cohort for NMRA-511.
Worry ifThe data from NMRA-511 fails to meet expectations or is inconclusive.
Why it matters: Data from NMRA-898 will help us understand how well it works for schizophrenia. Good results could increase investor confidence.
Supportive ifThe company reports positive Phase 1 data for NMRA-898 in the second half of 2026.
Worry ifThe Phase 1 data for NMRA-898 is disappointing or shows no efficacy.